









Markets
/
Stocks
/
nasdaq-ghrs
/

GH Research PLC

GHRS

View Detailed Chart

14.240USD

-2.450-14.68%

Close 07/23, 16:00（ET）Quotes delayed by 15 min

883.28MMarket Cap

LossP/E TTM



GH Research PLC

14.240

-2.450-14.68%

Overview Company Financials

Financials

Intraday

30m

Today

-14.68%

5 Days

-17.64%

1 Month

+21.92%

6 Months

+62.19%

Year to Date

+103.43%

1 Year

+19.36%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

BUY

Current Rating

33.143

Target Price

98.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

GH Research PLC

GHRS

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(6)

Neutral(2)

Buy(5)

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.450

Buy

RSI(14)

58.153

Neutral

STOCH(KDJ)(9,3,3)

62.553

Sell

ATR(14)

1.428

Low Volatility

CCI(14)

83.733

Neutral

Williams %R

41.532

Buy

TRIX(12,20)

1.556

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

17.660

Sell

MA10

16.818

Sell

MA20

15.089

Sell

MA50

13.169

Buy

MA100

11.756

Buy

MA200

10.495

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.

Ticker SymbolGHRS

CompanyGH Research PLC

CEODr. Velichka (Villy) Valcheva, M.D.

Website